Comparing a New Fluorescence Staining Method With Frozen Section in Prostate Cancer Surgery
Compares a new fluorescence staining test with frozen section for diagnosing prostate cancer.
Plain-language title generated from the registry record
Registry title: Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery
Key facts
- Where
- Changsha, ChinaSee the site
Where in China
- Xiangya Hospital Central South UniversityChangsha, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xiangya Hospital of Central South University
- Trial code
- NCT07690462
- Record updated
- 8 July 2026
- Original description
This study aims to validate the accuracy of the infrared fluorescence rapid detection technique for the diagnosis of prostate biopsy specimens, and to compare it with intraoperative frozen section and conventional paraffin section (the gold standard), so as to evaluate its feasibility and value in clinical application.Read full original descriptionShow less
A Clinical Validation Study of Novel Infrared Fluorescence Rapid Staining Versus Conventional Frozen Section in Intraoperative Diagnosis of Prostate Cancer
This study aims to validate the accuracy of the infrared fluorescence rapid detection technique for the diagnosis of prostate biopsy specimens, and to compare it with intraoperative frozen section and conventional paraffin section (the gold standard), so as to evaluate its feasibility and value in clinical application.
Inclusion: All adult male patients who are scheduled to undergo prostate biopsy at the Department of Urology, Xiangya Hospital due to clinical suspicion (e.g., elevated PSA, abnormal digital rectal examination, or suspicious lesions on imaging); Patients whose cardiac, pulmonary, hepatic, renal, and coagulation functions are essentially normal and who are able to tolerate the biopsy procedure; The patient or their legally authorized representative has signed the written informed consent form.
Exclusion: Patients with any serious concomitant disease that, in the investigator's opinion, may interfere with the study results or increase the patient's risk (e.g., hypertensive crisis; decompensated cardiac insufficiency; severe internal or external hemorrhoids, perianal or rectal lesions, etc.); Patients in the acute infection phase or febrile period; Patients with severe bleeding tendency conditions who are unable to undergo biopsy.